IMPERA MEDICINES
LIVE

Serial Number

98459161

Owner

Impera Medicines, LP

Attorney

Aaron D. Hendelman

Filing Date

Mar 20, 2024

Add to watchlist:

No watchlists yet
View on USPTO

IMPERA MEDICINES Trademark

Serial Number: 98459161

IMPERA MEDICINES is a trademark filed by Impera Medicines, LP on March 20, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Impera Medicines, LP

6175 Nancy Ridge Dr
San Diego, CA 92121

Entity Type: 13

Trademark Details

Filing Date

March 20, 2024

Registration Date

Not Registered

Published for Opposition

December 3, 2024

Goods & Services

medicinal preparations for the treatment of infectious diseases and for use in oncology; biological preparations for the treatment of cancer; anti-cancer preparations; medicinal preparations for the treatment of cardiometabolic diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cardiometabolic diseases; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, cardiometabolic, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

investment consultancy for biotechnology companies; investment management for biotechnology companies; financial services, namely, investment management and advisory services in the field of biotechnology; intellectual property venture fund management services in the field of biotechnology

research and development services in the fields of immunology and oncology; research and development services in the field of cardiometabolic diseases; medical research in the field of oncology; medical research in the field of immunology; medical research in the field of cardiometabolic diseases; research, development, engineering and testing services in the field of pharmaceuticals for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, cardiometabolic, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

Business consultancy in the field of biotechnology; professional business consulting for biotechnology companies; business consulting, business management and providing information in the biotechnology business field; business services, namely, assisting the owners of intellectual property and intangible assets in the field of biotechnology in finding investors

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 6, 2026 EXRA
SOU EXTENSION 2 GRANTED
Jan 6, 2026 EX2G
SOU EXTENSION 2 FILED
Jan 5, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 5, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 17, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jun 16, 2025 EX1G
SOU EXTENSION 1 FILED
Jun 16, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 16, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 14, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 11, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 4, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 4, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 4, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 4, 2024 CNEA
ASSIGNED TO EXAMINER
Sep 28, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 16, 2024 NWOS
NEW APPLICATION ENTERED
Mar 20, 2024 NWAP